- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.

$AVXL amazing avxl still in singke digits after a supposedly amazing “pivotal” trial readout 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Sava has potential and the phase 3 results will show the truth.

Australia has many advantages as a place to conduct clinical trials.

The phase 2b malaria vaccine is a blockbuster in the making and is leagues above the over 100 malaria vaccine candidates developed over the last 30 years.

Good Phase 3 results, and FDA is giving them a 4 month shortcut on approval. Shocking!

The current large-scale clinical trials and statistical data show that Novavax is 90% effective in preventing "all variants” and 100% in preventing severe diseases.

$NVAX well suited for our nvax even their trial name : backwards and upside down.

"From our UK study, we recently published that our vaccine had 82% efficacy for preventing all infections over six-month observation period.

The NeoCart trial will be successful, that will be our cash cow in the medium term.

Business is going well and we’re on target with an estimated 35 years until one of our experiments are finished with trials.

$ADXN as a successful former business owner and successful investor, I think that after this company tripling and now expecting epilepsy news, they are 1000% bullish they are going to going to the next phase with Johnson & Johnson.

the eye clinical trials are ongoing w good result to date!

And we still have covaxin- really the only widely used vaccine that hasn’t had reports of mass serious side effects- over 350Million doses and trials in USA have gone well.

👇🏻 Proud to announce positive Phase 2/3 data for our injectable COVID-19 vaccine candidate.

Ocugen hit all their endpoints in their trials !!

Importantly, the trial achieved both co-primary endpoints, and Covaxin was observed to be well tolerated in subjects.